Similar biological activity was replicated in models with activating RET mutations, including MTC cell lines and PDX models, and in PDX models with RET amplifications [109,111,112,113], providing insights into the druggability of RET alterations by MKIs initially designed for other indications. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.